Your Article Summary
See Latest ArticlesRepeat prostate biopsy — when, where, and how
Urologic Oncology: Seminars and Original Investigations, 07/02/09
Presti JC - In a review of the indications and techniques in pts undergoing a repeat biopsy, it appears that in pts for whom repeat biopsies fail to identify cancer, yet clinical suspicion remains high, consideration for a saturation biopsy approach seems warranted.
Methods- Pts who have a persistently elevated or a rising PSA level following a prior negative prostate biopsy can be a stressful situation for both urologist and pt.
- In pts with a prior negative biopsy, assessing the adequacy of the initial biopsy is important.
- F/T PSA is currently the most useful marker in predicting cancer on repeat biopsy, although newer markers, such as PCA3, are promising.
- Repeat biopsies should include a minimum of 14 cores, the 12 cores recommended for an initial biopsy and 2 additional cores obtained from the right and left anterior apex.
Related Articles
Detection rate and factors predictive the presence of prostate cancer in patients undergoing ultrasonography-guided transperineal saturation biopsies of the prostate
BJU International, 11/06/09
Relevance Score: 70%
Caudal analgesia for prostate biopsy
Acta Anaesthesiologica Scandinavica, 11/18/09
Relevance Score: 69%
Gleason score and laterality concordance between prostate biopsy and prostatectomy specimens
International Braz J Urol, 11/03/09
Relevance Score: 69%
Exercise and Prostate Cancer Risk in a Cohort of Veterans Undergoing Prostate Needle Biopsy
The Journal of Urology, 10/19/09
Relevance Score: 69%
Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended
BJU International, 10/13/09
Relevance Score: 69%
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Imprint cytologic features of chromophobe renal cell carcinoma morphologically resembling renal oncocytoma: Is this an oncocytic variant of chromophobe renal cell carcinoma
Diagnostic Cytopathology, 12/07/09
Blood pressure and risk of prostate cancer: Cohort Norway (CONOR)
Cancer Causes and Control, 12/07/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/07/09